# Wave Life Sciences, Inc.: overview

WVE · Nasdaq · CIK 1631574 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wve.md) · [Financials](/companies/wve/financials.md) · [Filings](/companies/wve/filings.md) · [Insiders](/companies/wve/insiders.md)

Latest reported revenue: [$13.2m](/filings/0001193125-26-432714.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 27, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-432714).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [9.2](/filings/0001193125-26-183587.md) | [8.7](/filings/0001193125-26-324949.md) | [7.6](/filings/0001193125-26-432714.md) | [17.2 d](/filings/0001193125-26-073472.md) | [38.2](/filings/0001193125-26-183587.md) | [2.3](/filings/0001193125-26-324949.md) | [13.2](/filings/0001193125-26-432714.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(542.8%)](/filings/0001193125-26-183587.md) | [(606.5%)](/filings/0001193125-26-324949.md) | [(740.7%)](/filings/0001193125-26-432714.md) | [(327.4%) d](/filings/0001193125-26-073472.md) | [(81.8%)](/filings/0001193125-26-183587.md) | [(3248.3%)](/filings/0001193125-26-324949.md) | [(502.0%)](/filings/0001193125-26-432714.md) |
| Net margin | % | not reported | [(510.9%)](/filings/0001193125-26-432714.md) | [(580.2%)](/filings/0001193125-26-432714.md) | [(707.8%)](/filings/0001193125-26-432714.md) | [(308.4%) d](/filings/0001193125-26-073472.md) | [(68.2%)](/filings/0001193125-26-432714.md) | [(3052.6%)](/filings/0001193125-26-432714.md) | [(470.5%)](/filings/0001193125-26-432714.md) |
| Diluted EPS | $ per share | not reported | [(0.29)](/filings/0001193125-26-183587.md) | [(0.31)](/filings/0001193125-26-324949.md) | [(0.32)](/filings/0001193125-26-432714.md) | not reported | [(0.13)](/filings/0001193125-26-183587.md) | [(0.34)](/filings/0001193125-26-324949.md) | [(0.30)](/filings/0001193125-26-432714.md) |
| Free cash flow | $m | [(43.7) d](/filings/0001193125-26-073472.md) | [(63.2)](/filings/0001193125-26-183587.md) | [(46.3) d](/filings/0001193125-26-324949.md) | [(44.9) d](/filings/0001193125-26-432714.md) | [(33.8) d](/filings/0001193125-26-073472.md) | [(60.0)](/filings/0001193125-26-183587.md) | [(54.5) d](/filings/0001193125-26-324949.md) | [(60.2) d](/filings/0001193125-26-432714.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [41.0](/filings/0000950170-23-009319.md) | [3.6](/filings/0000950170-25-031322.md) | [113](/filings/0001193125-26-073472.md) | [108](/filings/0001193125-26-073472.md) | [42.7](/filings/0001193125-26-073472.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(310.1%)](/filings/0000950170-23-009319.md) | [(4459.3%)](/filings/0000950170-25-031322.md) | [(60.0%)](/filings/0001193125-26-073472.md) | [(101.9%)](/filings/0001193125-26-073472.md) | [(504.1%)](/filings/0001193125-26-073472.md) |
| Net margin | % | [(298.4%)](/filings/0000950170-23-009319.md) | [(4434.7%)](/filings/0000950170-25-031322.md) | [(50.8%)](/filings/0001193125-26-073472.md) | [(89.6%)](/filings/0001193125-26-073472.md) | [(478.3%)](/filings/0001193125-26-073472.md) |
| Diluted EPS | $ per share | [(2.36)](/filings/0000950170-23-009319.md) | [(2.05)](/filings/0000950170-25-031322.md) | [(0.54)](/filings/0001193125-26-073472.md) | [(0.70)](/filings/0001193125-26-073472.md) | [(1.21)](/filings/0001193125-26-073472.md) |
| Free cash flow | $m | [(89.6)](/filings/0000950170-23-009319.md) | [(129)](/filings/0000950170-25-031322.md) | [(20.5)](/filings/0001193125-26-073472.md) | [(152)](/filings/0001193125-26-073472.md) | [(188)](/filings/0001193125-26-073472.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/wve/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2025-12-11 | [GSK plc](/insiders/1131399.md) | 10% owner | Purchase (P) | 1,470,000 | $19.00 | $27.9m | [Form 4](/filings/0001999371-25-020336.md) |
| 2024-09-27 | [GSK plc](/insiders/1131399.md) | 10% owner | Purchase (P) | 2,791,930 | $8.00 | $22.3m | [Form 4](/filings/0001999371-24-012789.md) |
| 2023-12-07 | [GSK plc](/insiders/1131399.md) | 10% owner | Purchase (P) | 3,300,000 | $5.00 | $16.5m | [Form 4](/filings/0001999371-24-001192.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [KENNEDY CAPITAL MANAGEMENT LLC](/funds/884589.md) | 2026-06-30 | $2.5m | 429,121 |  | New +429,121 |

## Recent filings

[All 726 filings](/companies/wve/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-27 | 07:50 ET | [10-Q](/filings/0001193125-26-432714.md) | Quarterly report, period 2026-09-30 | 0001193125-26-432714 |
| 2026-10-27 | 07:35 ET | [8-K](/filings/0001193125-26-432690.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-432690 |
| 2026-10-14 | 17:14 ET | [DEF 14A](/filings/0001193125-26-421806.md) | Proxy statement, period 2026-11-12 | 0001193125-26-421806 |
| 2026-08-11 | 16:39 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000222.md) | Ownership report, active investor, amended | 0001346824-26-000222 |
| 2026-07-30 | 07:50 ET | [10-Q](/filings/0001193125-26-324949.md) | Quarterly report, period 2026-06-30 | 0001193125-26-324949 |
| 2026-07-30 | 07:38 ET | [8-K](/filings/0001193125-26-324917.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-324917 |
| 2026-06-26 | 08:30 ET | [8-K](/filings/0001193125-26-284002.md) | 5.07 Shareholder vote results | 0001193125-26-284002 |
| 2026-05-18 | 16:51 ET | [8-K](/filings/0001193125-26-229076.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-229076 |
| 2026-05-07 | 16:01 ET | [DEF 14A](/filings/0001193125-26-211828.md) | Proxy statement, period 2026-06-22 | 0001193125-26-211828 |
| 2026-04-30 | 16:15 ET | [10-K/A](/filings/0001193125-26-197330.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-197330 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-073472.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/027c0893-499b-4e3a-8a5d-1ca8098e3e09)

## About the filer

- CIK: 1631574
- Tickers: WVE
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:33 ET. No prices; not investment advice.